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Induction of E-selectin on endothelial cell surface initiates leukocyte adhesion and subsequent migration into the subendothelium. Here,
we tested the effect of hepatocyte growth factor (HGF) on inflammatory cytokine-induced expression of E-selectin and consequent
leukocyte–endothelial cell interaction using human umbilical vein endothelial cells (HUVEC). Prior treatment of HUVEC with HGF
significantly attenuated the tumor necrosis factor (TNF)-a-induced E-selectin protein, adhesion of HL60 cells to HUVEC and E-selectin
mRNA expression in a dose-dependent manner, while HGF itself did not exert any effects. The HGF effects on the mRNA expression were
inhibited in the presence of NG-nitro-L-arginine methyl ester (L-NAME), a nitric oxide synthase (NOS) inhibitor, which also abolished HGF-
stimulated eNOS activity. These results suggest HGF plays cardiovascular protective functions mediated, at least in part, through nitric oxide-
dependent suppression of inflammatory cytokine-induced E-selectin expression and subsequent tethering of leukocytes to endothelial cells.
D 2003 Elsevier B.V. All rights reserved.Keywords: HGF/SF; Cell adhesion molecule; eNOS; E-selectin; Nitric oxide; L-NAMEHepatocyte growth factor (HGF), also known as Scatter
factor (SF), is a multipotential cytokine that can exert
various responses in target cells including endothelial cell
growth, motility and organization into tube-like structures
[1–3]. HGF also plays pivotal role in some tumor invasion
and metastasis by altering the expression of proteolytic
enzymes and cell adhesion molecules [4,5]. In endothelial
cells HGF activates the phosphatidylinositol 3-kinase
(PI3K) and mitogen-activated protein kinase (MAPK) path-
ways through its tyrosine kinase receptor, c-Met, to subse-
quently alter transcription of various genes including those
involved in cell survival [6,7].0167-4889/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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functional and antigenic changes, including reduced nitric
oxide (NO) bioavailability as a result of endothelial isoform
of nitric oxide synthase (eNOS) dysregulation [8,9], and
increased expression of leukocyte adhesion molecules such
as vascular cell adhesion molecule (VCAM)-1, intercellular
adhesion molecule (ICAM)-1 and E-selectin [10,11]. These
events promote peripheral leukocyte–endothelial cell inter-
actions and subsequent subendothelial migration and exces-
sive smooth muscle proliferation, leading to atherosclerosis
[11,12]. Interestingly, HGF induces leukocyte counterli-
gands expression to promote migration of T-cell subsets
[13] and adhesion of neutrophils on activated endothelial
monolayer [14]. HGF also promotes shedding of L-selectin
[14], a constitutively expressed adhesion molecule on the
surface of leukocytes that mediates initial leukocyte attach-
ment to the endothelium [10–12]. These cellular processes
suggest that HGF may exacerbate atherogenesis.
In experimental vascular injury, however, HGF attenu-
ates neointimal proliferation through enhanced endothelial-
ization [15] and promotes cellular cardiomyplasty through
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and c-Met show increased localized expression after myo-
cardial ischemic injury [17,18] and also in endothelial cells
exposed to atherogenic modified LDL [19]. This is probably
a protective mechanism against insult since HGF lacks the
activities related to hemostasis-thrombosis and inflamma-
tion [2], but instead inhibits proinflammatory endothelin-1
release [19]. Therefore, it is plausible to speculate that HGF
actually plays protective functions against inflammation
and/or injury in the cardiovascular system.
To test this hypothesis, we examined whether HGF
modulates the inflammatory cytokine-induced expression
of cell adhesion molecule, E-selectin, and the consequent
propensity of leukocyte adhesion to human umbilical vein
endothelial cells (HUVEC). Further, we examined the
mechanisms through which HGF mediates the protective
functions by focusing on eNOS, a key molecule in the
maintenance of cardiovascular homeostasis.1. Materials and methods
1.1. Materials
Recombinant human HGF was a generous gift of Mitsu-
bishi Pharma (Tokyo, Japan). Recombinant human tumor
necrosis factor-a (TNF-a) was obtained from Strathman
Biotech (Hamburg, Germany). NOS inhibitor, NG-nitro-L-
arginine methyl ester (L-NAME), was from Dojindo (Kuma-
moto, Japan) and PI3K inhibitor, wortmannin, was from
Sigma-Aldrich (St. Louis, MO, U.S.A.).
1.2. Cell culture
HUVEC were cultured on Type I-collagen-coated culture
plates (100-mm plates, Iwaki, Asahi Techno Glass, Chiba,
Japan) in MCDB-104 medium (Morinaga Institute of Bio-
logical Science, Yokohama, Japan) containing 10% fetal
bovine serum (FBS) and 12.5 mM HEPES and supple-
mented with brain-extracted growth factors (Morinaga In-
stitute of Biological Science) at 37 jC and 5% CO2 under
humidified conditions. After cells were grown to conflu-
ence, they were serum-starved in phenol red-free Medium
199 (Sigma-Aldrich) supplemented with 2 mM L-glutamine
and 0.2% bovine serum albumin (BSA) for overnight prior
usage. All the experimental treatments were carried using
fresh serum-starvation medium.
1.3. Cell ELISA
Cell ELISA was performed as previously reported with
minor modifications [20]. Briefly, HUVEC in type I-colla-
gen-coated 24-well plates were treated as indicated in the
figure legends with TNF-a with or without HGF pretreat-
ment. Following the treatments, the cells were next exposed
to a monoclonal mouse anti-human E-selectin antibody(Dako, Glostrup, Denmark) at 1:1000 dilution in the se-
rum-starvation M199 medium for 1 h at room temperature.
Cells were washed and then incubated with a horseradish
peroxidase-conjugated goat anti-mouse IgG (Jackson Immu-
noResearch Laboratories, West Grove, PA, USA) at 1:5000
dilution in M199 for a further hour. Color formation with
TMB (3, 3V, 5, 5V-tetramethylbenzidine, Moss Pasadena, MD,
USA) after 10-min exposure was measured at 450 nm.
1.4. Cell adhesion assay
The adhesion of human myelogenous leukemic cell line
HL60 to HUVEC was performed as previously described
[20,21] with minor modifications. Briefly, regularly pas-
saged HL60 cells were labeled with fluorescent dye, 2V,7V-
bis(2-carboxyethyl)-5(6)-carboxyfluorescein acetoxymethyl
ester (BCECF-AM, Sigma-Aldrich) at 10 AM final concen-
tration in RPMI-1640 medium (Sigma-Aldrich) containing
10% FBS at 37 jC for 1 h. The labeled cells were harvested
by centrifugation and washed three times with phosphate-
buffered saline (PBS) before suspension in the medium, and
added to HUVEC in six-well culture plates at 4 105 cells/
ml. The co-incubation was done at 37 jC for 30 min, and
unbound HL60 cells were removed by stringent washing
four times with medium (RPMI-1640, 1% FBS), and finally
twice with PBS. HL60 cells bound to HUVEC were lysed
with 50 mM Tris–HCl, pH 8.0, containing 0.1% SDS, and
fluorescence measured on a spectrofluorometer (Jasco,
Tokyo, Japan) at 485-nm excitation and 530-nm emission
wavelenght.
1.5. Total RNA isolation and Northern blot analysis
After the treatments of HUVEC, total cellular RNA was
isolated by the guanidine isothiocyanate method [22] using
TRIzol reagent (Gibco BRL, Gaithersberg, MD, USA)
following the manufacturer’s protocol. Total RNA concen-
tration and purity was determined using a spectrophotomet-
ric method at 260/280 nm. The expression of cell adhesion
molecule, E-selectin mRNA, was determined by Northern
blot analysis. Briefly, total RNA (15 Ag) was resolved on
1% agarose-formaldehyde gel stained with ethidium bro-
mide, transferred onto a nitrocellulose membrane (Hybond-
N, Amersham Pharmacia Biotech, Buckinghamshire, UK)
and cross-linked under UV light for 2 min. Both prehybrid-
ization and hybridization were performed at 65 jC for 4
h and overnight, respectively, in a buffer containing 7%
SDS, 0.5 M Church’s phophate buffer, pH 7.2, 1 mM EDTA
and 1 mg/ml salmon sperm DNA. After prehybridization,
the membrane was sequentially hybridized with a cDNA
probe encoding human E-selectin and a mouse glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH) probe as
the internal control for loading. The E-selectin probe,
718–1319 nucleotides (GenBank accession NM00450),
was amplified by RT-PCR method using RNA template
from HUVEC and primers (forward: GCTACAATTC-
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TAGCCTCG), and subcloned into pGEMR-T Easy vector
(Promega, Madison, WI, USA). The nucleotide sequence
of the probe was confirmed and then labeled with
[a-32P]dCTP using the Megaprimek DNA labeling sys-tems (Amersham) according to the instructions provided.
After hybridization, the membrane was stringently washed
first in buffer A (0.2% SSC, 0.1% SDS) and then in
buffer B (0.1% SSC, 0.1% SDS) at 65 jC before
exposure onto a phospho-imaging plate overnight. Detec-
tion and quantification of the hybridization signals were
carried out using a phosphoimage analyzer (BAS 2500,
FUJIFILM, Tokyo, Japan).
1.6. Measurement of eNOS activity
The eNOS activity was quantified as the conversion of L-
[U-14C] arginine to L-[U-14C] citrulline as previously de-
scribed [23] with minor modifications. Briefly, confluent
HUVEC were serum-starved and the medium replaced
before the treatments. Following the experimental treat-
ments, cells were harvested in ice-cold homogenization
buffer containing 50 mM Tris–HCl pH 7.4, 250 mM
sucrose, 0.1 mM EGTA, 0.1 mM EDTA, 1 mM dithiothrei-
tol (DTT), and a protease inhibitor cocktail, Complete (1
tablet/50 ml, Roche Diagnostics, GmbH, Mannheim, Ger-
many). For each sample 10 Al of homogenate was incubated
in duplicate at 37 jC for 10 min in a 100 Al of reaction
mixture containing 50 mM HEPES, pH 7.9, 1 mM DTT, 1
mM CaCl2, 0.1 mM tetrahydro-L-biopterin (BH4), 1 mM
NADPH, 10 AM FAD, 10 Ag/ml calmodulin and 1.43 AM L-
[U-14C] arginine (Amershan). The reaction was terminated
by addition of 200 Al of a stop solution containing 100 mM
HEPES and 10 mM EDTA, pH 5.2. The reaction mixture
was then applied to 0.5-ml neutralized AG 50W-X4 resin
(Na+ form 200–400 mesh, Bio-Rad Labs, Hercules, CA,
USA) column to separate L-[U-14C] citrulline. The flow-
through was analyzed by liquid scintillation counting and
enzyme activity expressed as fmol of L-[U-14C] citrulline
produced/mg protein of homogenate/10 min. Protein con-
centration was determined by the Lowry method [24] using
BSA as a standard.
1.7. Statistical analysis
All experiments were repeated at least four times unless
otherwise indicated. Results are expressed as meansF S.E.Fig. 1. HGF suppresses TNF-a-induced expression of E-selectin in
HUVEC. Confluent HUVEC were serum-starved in phenol red-free
medium, M199 for 4 h (A, B) and overnight (C) before stimulation. Cells
were stimulated with the indicated doses of HGF for 30 min before TNF-a
(1 ng/ml) challenge for 4 h. Cell surface expression of adhesion molecule,
E-selectin protein, on HUVEC was determined by ELISA (A) while HL60
cell adhesion to HUVEC was quantified by a fluorescent dye, BCECF-AM
assay system as outlined in the Materials and methods (B). The E-selectin
mRNA expression in 15 Ag of each sample was determined by Northern
blot analysis (C). Shown in (A) is fold increase in absorbance (450 nm), (B)
is fold increase in fluorescence and (C) are representative blots and
densitometric analyses, all expressed relative to TNF-a treatment. Results
represent the meanF S.E. of four independent experiments [in triplicates
for (A, B)]. *P< 0.05 vs. untreated control. yP < 0.05 vs. TNF-a treatment
alone.
Fig. 2. HGF induces activation of eNOS in HUVEC. Confluent HUVEC
were serum-starved overnight and stimulated with different doses of HGF
for 20 min. The eNOS activity in the cell homogenate was determined as
the conversion of L-[U-14C] arginine to L-[U-14C] citrulline, and expressed
as fold increase relative to the controls (untreated). Results represent the
meanF S.E. of four independent experiments. *P < 0.05 vs. without HGF
addition (dose 0).
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(ANOVA) and Fischer’s test at P < 0.05.Fig. 3. Effect of NOS inhibitor, L-NAME, and PI3K inhibitor, wortmannin,
on the HGF-stimulated eNOS enzyme activity. HUVEC were treated with
L-NAME (1 mM) and wortmannin (WT, 500 nM) for 30 min prior to HGF
(40 ng/ml) for 20 min. Then eNOS activity in the cell homogenate was
assayed and expressed as fold increase relative to controls (untreated).
Results represent the meanF S.E. of four independent experiments.
*P< 0.05 vs. without HGF addition. yP < 0.05 vs. HGF.2. Results
To test the hypothesis that HGF plays protective func-
tions during inflammation and/or injury in the cardiovascu-
lar system, we investigated its effects on inflammatory
cytokine, TNF-a-induced expression of cell adhesion mol-
ecule, E-selectin and the subsequent adhesion of leukocytes
to endothelial cells. As expected, treatment of HUVEC with
TNF-a (1 ng/ml) for 4 h strongly induced E-selectin protein
and this was accompanied with increased adhesion of HL60
cells to HUVEC (Fig. 1A and B). On the contrary, pretreat-
ment of HUVEC with increasing doses of HGF, 30 min
prior to the TNF-a challenge, dose-dependently suppressed
both the TNF-a-induced expression of E-selectin protein
and the consequent increased HL60 cells–HUVEC interac-
tion (Fig. 1A and B). The suppressive effects on E-selectin
protein expression were significant at the lowest dose (1 ng/
ml HGF) while those of HL60 cell adhesion were at
concentration of 5 ng/ml and above. Importantly, HGF
alone neither exerted any notable effects on the expression
of E-selectin protein nor the HL60 cell adhesion to HUVEC
(Fig. 1A and B).
Next, we examined whether HGF regulated the TNF-a-
induced E-selectin expression at the transcriptional level.
Similarly, to the increased E-selectin protein, the mRNA
expression was potently induced by the 4-h TNF-a treat-
ment (Fig. 1C). However, this increased E-selectin mRNA
expression was dose-dependently suppressed by HGF pre-
treatment, significantly at concentration of 5 ng/ml HGF andup to a maximum suppression of about 70% at the highest
dose (100 ng/ml HGF) used in this study (Fig. 1C). Again,
HGF alone did not exert any significant effects on the E-
selectin mRNA expression as observed for the protein and
adhesion of HL60 cells (Fig. 1).
Previous reports have demonstrated that HGF induces
endothelial cell motility through NO-mediated mechanisms
[25], and NO-donors suppress LPS-induced E-selectin ex-
pression [26]. Here, we also tested whether HGF modulates
eNOS activity and hence NO availability in endothelial cells
to mediate the suppressive effects. As shown in Fig. 2,
treatment of HUVEC with increasing doses of HGF for 20
min significantly stimulated eNOS activity monitored as the
conversion of arginine to citrulline. Increased eNOS activity
was evident at the lowest dose (1 ng/ml) and significantly
from 10 ng/ml of HGF. Maximum activation was obtained
at 40 ng/ml of HGF with no further increase at the highest
dose used in the experiments (Fig. 2). Prior treatment of
HUVEC with L-NAME, a NOS inhibitor, completely abol-
ished, while wortmannin, a PI3K inhibitor, significantly
attenuated but did not completely inhibit the HGF-stimulat-
ed eNOS activity (Fig. 3).
Further, we explored the link between the HGF suppres-
sion of TNF-a-induced expression of E-selectin mRNA and
the enhancement of eNOS activity and increased NO
production and bioavailability. As shown in Fig. 4A, prior
exposure of HUVEC to L-NAME completely abolished the
suppressive effects of HGF on the TNF-a-induced expres-
sion of E-selectin mRNA, while L-NAME alone did not
exert any effects. Wortmannin also completely abrogated the
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expression (Fig. 4B). The PI3K blockade was not only
suppressive to the HGF effects but also induced E-selectin
mRNA expression (Fig. 4B).3. Discussion
Using HUVEC in culture, we have demonstrated that
HGF markedly suppresses the inflammatory cytokine, TNF-
a-induced expression of cell adhesion molecule, E-selectin
and adhesion of HL60 cells in a dose-dependent manner,
clearly indicating direct protective functions on vascular
endothelial cells (Fig. 1). This report provides the first
evidence that HGF modulates the expression of atherogenic
cell adhesion molecules and consequently the critical step of
leukocytes adhesion on vascular endothelial cells during
inflammation and/or injury. E-selectin is rapidly induced by
inflammatory cytokines and recognizes carbohydrate
ligands on leukocytes leading to rolling and tethering and
further activation of the adhesion process [10,11]. There-
fore, reduction in E-selectin and the propensity of leukocyte
adhesion to endothelial cells undoubtedly slows the devel-
opment and progression of atherosclerosis. Indeed, animal
models deficient in P- and E-selectins develop less severe
atherosclerosis [27].
The role of NO in the maintenance of cardiovascular
homeostasis is unequivocal [28], and previous studies have
demonstrated that NO modulates the inflammatory cyto-
kine-induced expression of cell adhesion molecules [26]. In
this study, HGF dose-dependently stimulated eNOS activ-
ity in HUVEC that was inhibited by L-NAME and signif-
icantly attenuated by wortmannin. More importantly, these
inhibitors abolished the suppressive effects of HGF on
TNF-a-induced E-selectin mRNA expression. Here, al-
though we did not examine the suppressive mechanisms
in detail, the findings suggest NO is involved in the HGF
effects probably by modulating E-selectin expression at the
transcriptional level [26], and consequently the protein
expression.
Recently, we observed that HGF rapidly stimulates
eNOS activity in bovine aortic endothelial cells (BAEC),
accompanied with increase of activity-related site-specific
phosphorylation of this enzyme [29]. Similarly, HGF stim-
ulation in HUVEC was rapid, suggesting that eNOS is
responsible for the HGF suppression of TNF-a-induced E-
selectin expression and subsequent adhesion of HL60 cells
to HUVEC. It is of interest that involvement of inducible
nitric oxide synthase (iNOS) after 4-h incubation is possible
since HGF enhances NO production by up-regulation iNOS
protein levels through a PI3K-dependent mechanism in
endothelial cells [25]. However, these effects are mostFig. 4. Effect of L-NAME and wortmannin on the HGF suppression of
TNF-a-induced expression of E-selectin mRNA on HUVEC. Confluent
HUVEC were treated with L-NAME (1 mM) (A) and wortmannin (WT, 500
nM) (B) before sequential stimulation with HGF (100 ng/ml) and TNF-a (1
ng/ml) for 4 h. Northern blot analysis was performed as earlier outlined.
Representative blots and densitometric analyses expressed relative to TNF-
a treatment are shown. Results represent the meanF S.E. of three (A) and
four (B) independent experiments. *P < 0.05 vs. untreated control. yP < 0.05
vs. TNF-a treatment alone.
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potently up-regulated with inflammatory cytokines includ-
ing TNF-a [30].
HGF alone had absolutely no effects on either E-selectin
expression or adhesion of HL60 cells, consistent with the
fact that HGF lacks inflammatory activities. In stark con-
trast, HGF activates adhesion molecules on T-cells [13] and
neutrophils [14], and also promotes monocyte-macrophage
differentiation and function [31,32], events that can accel-
erate their attachment on the endothelium. Thus, HGF
seems to have dual functions in the leukocyte–endothelial
cell interactions, and further studies to resolve these specific
roles are necessary.
In summary, we have demonstrated for the first time that
HGF suppresses TNF-a-induced expression of E-selectin
and adhesion of HL60 cells to HUVEC through NO-
mediated mechanisms. These findings provide valuable
information for strategic therapeutic use of HGF for various
cardiovascular disorders and angiogenesis.Acknowledgements
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